134 results about "Cannabinoid" patented technology

A method for cooking savory food with a cannabinoid containing mixture. The method comprising the general steps of making a cannabinoid containing mixture and mixing the cannabinoid containing mixture with a savory food item, such as a brisket. In one exemplary embodiment, the cannabinoid containing mixture comprises brown sugar, garlic powder, onion powder, salt, black pepper, cajun seasoning, peppercorn pepper, white sugar, and a therapeutic amount of CBD or THC. If desired, a spicey component, such as habanero peppers, may be added to the cannabinoid containing mixture to add heat.

Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.

The present invention is based on the highly soluble and bioavailable cannabinoid compositions which can be made at a commercial scale with a simple manufacturing process. Thus, the present invention relates to oral compositions comprising a cannabinoid compound, for use in the nutraceutical, pharmaceutical, food or beverage industries and its production methods.

Compositions comprising 0.1-50 % delta-9-tetrahydrocannabinol and / or cannabidiol in forms suitable for continuous delivery and use thereof in the treatment of a variety of diseases and pathological disorders are disclosed. In preferred embodiments, the compositions are in a form suitable for delivery via a portable infusion pump or transdermal patch. The disorders to be treated include pain, cancer, seizure disorders, and Parkinson's disease. Depending on the disorder to be treated, the compositions may optionally further comprise additional active agents such as dopaminergic agents.

Methods for the asymmetric hydrogenation of the trisubstituted olefin in THC are disclosed. The methods disclosed herein can be performed in conventional organic solvents or in water under modified Pickering catalysis conditions. The methods disclosed herein provide improved selectivity over standard industrial conditions with decreased reaction times under ambient conditions.

The present invention provides a novel room-temperature extraction system and method for cannabis and hemp, utilizing custom membrane filtration to efficiently isolate cannabinoids, terpenes, and other bioactive compounds while reducing energy consumption. This multi-stage system begins with a custom milling machine that preprocesses biomass by separating non-target components, such as cellulose-rich stalks, to improve extraction efficiency. The core extraction process employs a series of custom membranes designed to selectively filter cannabinoids and terpenes, minimizing impurities without the need for traditional sub-zero cooling. Each membrane stage incorporates solvent recovery to recycle ethanol, reducing waste and operational costs. In the final stage, a custom concentrator removes residual ethanol, decarboxylates THCa to THC, and crystallizes sugars to prevent downstream clogging. This room-temperature extraction system significantly enhances yield, purity, and sustainability, making it a scalable and cost-effective solution for cannabis and hemp processing industries, as well as applicable for pharmaceutical and nutraceutical uses.

Methods of stabilizing acidic cannabinoids by intercalating the acidic cannabinoids into layered double hydroxides (LFHs) are provided. Also provided are compositions comprising the LDH-intercalated acidic cannabinoids, physiologically compatible formulations comprising the compositions and methods of using the formulations to treat a variety of diseases and conditions in subjects.

A black pepper cannabinoid extract includes beta-caryophyllene and five or more other terpenes. The invention also relates to a method of producing the black pepper cannabinoid extract, including the steps of: extracting black pepper to produce a first extract having fat-soluble components; winterizing the first extract to remove components differentiated by a higher solidification temperature; fractionally distilling the winterized fat-soluble components of the first extract to produce a plurality of black pepper lipid fractions; and blending two or more of the black pepper lipid fractions to produce a black pepper cannabinoid extract. The black pepper cannabinoid extract includes beta-caryophyllene and five or more other terpenes.

Provided herein are terpenoid- and cannabinoid-encapsulating PLGA nanoparticles and pharmaceutical compositions comprising the nanoparticles. Further provided are methods of making and using the terpenoid- and cannabinoid-encapsulating PLGA nanoparticles for therapeutic purposes.

Aspects of the disclosure provide a formulation for treating advanced pancreatic cancer, comprising a combination of a cannabinoid, a terpene, and a flavonoid. To enhance bioavailability and targeted delivery, the formulation is incorporated into a nanoplatform, such as a nanoemulsion, optimizing absorption and delivery to cancer cells. The nanoparticle-based composition specifically targets advanced stages of pancreatic cancer, aiming to inhibit tumor progression and improve clinical outcomes.

Provided herein are methods of treating cannabinoid intoxication. Further provided herein are metrics for evaluation Cannabis intoxication and the amelioration thereof.

The present invention relates to a method for treatment of cancer, e.g., breast cancer, by administration of an active agent combination comprising sinigrin, vitexin, taraxasterol, and a cannabinoid such as CBD, as well as to a kit for carrying out said method, and a composition comprising said active agent combination.

A sensing module for monitoring dosage delivery of a vaporized material, and a portable vaporization unit including the sensing module, include a light sensor that detects disruptions in a light path across a vapor channel, the disruptions caused by the vaporized material flowing through the vapor channel. The light sensor includes a UV light source, which may emit 370 nm wavelength light, and a UV light detector that converts intensity of incident light in the light path into a signal. A microprocessor of the sensing module compares the signal to a baseline measurement to determine the concentration of a medicament in the vapor; then, using the flow rate and activation time of the device, the microprocessor determines the dosage and can perform monitoring and reporting actions based on the dosage. A measuring circuit measures fluctuations in resistance / impedance of a vaporization element to further determine flow rate and / or dosage.

The present disclosure provides cannabinoid formulations, more particularly pharmaceutical formulations which are highly-loaded with cannabinoids. The formulations are suitable for self-emulsifying into emulsions that are characterized by a stable mono-modal narrow droplet size distribution, and suitable for administration to subjects in need of cannabinoids administration for treatment of various conditions.

The invention relates to an oral cannabinoid formulation comprising: a cannabinoid component comprising a cannabinoid; a carrier in the form of long chain triglyceride (LCT) or long chain fatty acid (LCFA); and a tocopheryl phosphate component comprising mono-(tocopheryl) phosphate (TP) and di-(tocopheryl) phosphate (T2P) wherein the mass ratio of the cannabinoid to the tocopheryl phosphate component is about 10:1 to 1:10.

Systems and methods for oxidizing phenolic cannabinoids with fuel cells are described. The oxidation processes for phenolic cannabinoids and / or Δ9-THC can be detected and the concentration of phenolic cannabinoids and / or Δ9-THC can be reported directly with fuel cells. Many embodiments provide integrating cannabinoid fuel cells into marijuana breathalyzer devices.

This invention relates to a novel cannabinoid oral pharmaceutical dosage form based on a Type IV or Type IV-like formulation classified using a Lipid Formulation Classification System. The formulation is contained in a container. "Type IV-like" means that the formulation is oil-free, for example, free of triglycerides or mixed glycerides.

This patent document discloses compositions, containers, and methods related to anionic cannabinoids that contain oxide substituents. The anionic cannabinoids may be prepared from cannabinoid molecules, for example, by contacting the cannabinoid molecules with a strong base. The anionic cannabinoids generally display improved solubility in water.

The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabinoids to target sites, including sites on the surface of and / or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and / or to treat ophthalmic conditions such as glaucoma.

To provide a pharmaceutical composition containing cannabidiol (CBD) for reducing the total seizure frequency in treatment of treatment-resistant epilepsy (TRE).SOLUTION: A pharmaceutical composition containing cannabidiol (CBD) to be used for treating treatment-resistant childhood epilepsy, where the CBD is present at an amount of reducing the total seizure frequency by more than 50% for the frequency of seizure achieved by a combined antiepileptic drug (AED). The treatment-resistant childhood epilepsy includes Dravet syndrome, epilepsy with myoclonic absence, Lennox-Gastaut syndrome and the like, and the CBD is used in combination with one kind or a plurality of antiepileptic drugs (AED).SELECTED DRAWING: None

The present disclosure provides cannabinoid drug substances, pharmaceutical compositions and methods of treating neurological or neurodegenerative disorders in a human patient.

The present disclosure relates to drug-containing particles comprising one or more cannabinoids and a porous solid carrier. In embodiments, the one or more cannabinoids are adsorbed onto and / or in a porous solid carrier. In embodiments, the drug-containing particles exhibit improved solubility and bioavailability, among other beneficial properties. Methods of preparation and pharmaceutical compositions are also described.

The present invention relates to compositions comprising a mixture comprising or, alternatively, consisting of a turmeric extract and at least one compound selected from the group comprising or, alternatively, consisting of cinnamon oil and thymol for use in the treatment, preventive and / or curative, of at least one joint pathology of an inflammatory and / or degenerative nature and / or of a symptom associated therewith in human beings, or monogastric animals, by modulation of the receptors and / or enzymes of the endocannabinoid system.